Founded within MIT campus, we are a diverse team of phage and biological engineers harnessing the human phageome to develop a next-generation delivery platform for redosable genomic medicines. We believe in thinking outside of the box and are pioneering a multidisciplinary approach in developing our phage-derived particle (PDP) technology for in-vivo gene therapies.